Prospective Analysis of Patients with Heart Failure with Mildly Reduced Ejection Fraction: A Tertiary Care Observational Study
Published: 2024-02-21
Page: 13-24
Issue: 2024 - Volume 7 [Issue 1]
Hemnath C. *
Apollo Main Hospitals, Chennai-06, India.
Asha Mahilmaran
Apollo Main Hospitals, Chennai-06, India.
*Author to whom correspondence should be addressed.
Abstract
Background: Heart failure (HF) is growing in epidemic proportion due to a spectrum of cardiovascular diseases leading to myocardial dysfunction. HF with mildly reduced ejection fraction (HFmrEF) is a unique phenotype of HF with differences in clinical features as compared to other phenotypes of HF.
Materials and Methods: A single center tertiary care hospital-based prospective observational study comprising urban/rural based 157 patients aged 18 years. Heart failure of any etiology will be included after primarily excluding Sepsis as an inciting factor for worsening/initiation of HFmrEF. These patients will be followed up for a period of 6 months with their clinicopathological correlates.
Results: Study analysis revealed Male sex, overweight BMI subset, NYHA class at presentation, presence of CAD & CKD predicted both incident and worsening HFmrEF. Hospitalized patients with HFmrEF have more morbidity and mortality than ambulatory patients. HF with mildly reduced LVEF in their lower range (LVEF 41-45%) had a poor prognosis compared to those with upper ranges of HFmrEF (46-49%). There were patient and drug-related factors in initiating core heart failure medications as suggested by ESC HF guidelines
Conclusion: Heart failure with mildly reduced ejection fraction is a clinical spectrum of heart failure characterized as a transitioning stage in the natural course of heart failure. There are significant differences in patient profiles demanding individualized protocol for addressing specific triggers and targets of HFmrEF. Phenotyping, treatment options, early achievement in LVEF recovery, and serial follow-up of LVEF with echocardiography of this small subset of HF will help in changing the trajectory of natural history of HFmrEF patients.
Keywords: Heart failure ejection fraction, coronary artery disease, chronic kidney disease, recurrent heart failure hospitalization
How to Cite
References
Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: Current epidemiology and future directions. Circulation. 2016;133(16):1605-20.
Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk. J Am Coll Cardiol. 2022;80(25):2361-71.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23 (3):352-80.
Huffman MD, Prabhakaran D. Heart failure: Epidemiology and prevention in India. Natl Med J India. 2010;23(5):283-8.
Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report from the American Heart Association. Circulation. 2016;133(4):447-54.
Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J Off J Jpn Circ Soc. 2013;77(9):2209-17.
Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, et al. Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Fail. 2016;3(3):145–51.
Lam CSP. Heart failure in Southeast Asia: facts and numbers. ESC Heart Fail. 2015; 2(2):46-9.
Harikrishnan S, Bahl A, Roy A, Mishra A, Prajapati J, Nanjappa MC, et al. National Heart Failure Registry, India: Design and methods. Indian Heart J. 2019;71(6):488-91.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18): e895-1032.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24(2):335-50.
Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20(4):651-9.
Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):401-10.
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-16.
Catchpool M, Ramchand J, Hare DL, Martyn M, Goranitis I. Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scores. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2020;29(10): 2815-22.
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18 (6):613-25.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118 (17):3272-87.
Abeya FC, Lumori BAE, Akello SJ, Annex BH, Buda AJ, Okello S. Incidence and predictors of 6 months mortality after an acute heart failure event in rural Uganda: The Mbarara Heart Failure Registry (MAHFER). Int J Cardiol. 2018;264:113-7.
Farré N, Vela E, Clèries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. PloS One. 2017;12(2): e0172745.
Li P, Zhao H, Zhang J, Ning Y, Tu Y, Xu D, et al. Similarities and differences between HFmrEF and HFpEF. Front Cardiovasc Med. 2021;8:678614.
Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721-30.
Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685-94.
Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20(4):651-9.
Toma M, Ezekowitz JA, Bakal JA, O’Connor CM, Hernandez AF, Sardar MR, et al. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. Eur J Heart Fail. 2014;16(3):334-41.
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750–7.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet Lond Engl. 2003;362(9386): 777-81.
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62.
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8): 768-77.
Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721-30.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al. Heart failure with mid-range ejection fraction: A distinct clinical entity? Insights from the Trial of Intensified versus standard medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19 (12):1586-96.
Pandhi J, Gottdiener JS, Bartz TM, Kop WJ, Mehra MR. Comparison of characteristics and outcomes of asymptomatic versus symptomatic left ventricular dysfunction in subjects 65 years old or older (from the Cardiovascular Health Study). Am J Cardiol. 2011;107(11): 1667-74.
Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977–82.
Tsao CW, Lyass A, Larson MG, Cheng S, Lam CSP, Aragam JR, et al. Prognosis of adults with borderline left ventricular ejection fraction. JACC Heart Fail. 2016;4 (6):502-10.